InnoGene BioTech key facts
as of Oct 2026- Developer of green synthetic biological products.
- InnoGene BioTech is valued at approximately $27.0M as of Oct 2026 (last reported valuation).
- It has raised $41.5M; the latest was Early Stage VC ($20.6M) in Mar 2025.
- Notable investors include Hefei Industry Investment Group, Furong Capital, Flyfot Ventures, Fontus Capital, Hangzhou Huaiji Investment — 9 tracked in total.
- Status: Privately Held (backing).
InnoGene BioTech's last reported valuation, Dec 2022. Nothing priced has surfaced since.
- ·Watch InnoGene BioTech: the Monday email on marks, rounds and moves
InnoGene BioTech funding rounds
No funding rounds for InnoGene BioTech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
InnoGene BioTech valuation
InnoGene BioTech's last reported valuation was $27 million in Dec 2022. No priced round, secondary trade or fund mark has surfaced since.
InnoGene BioTech investors
9 investors are on record for InnoGene BioTech, including Hefei Industry Investment Group, Furong Capital, Flyfot Ventures and Fontus Capital.
About InnoGene BioTech
Developer of green synthetic biological products. This company's products are based on a synthetic biology platform with technologies in component mining, strain modification and screening, fermentation optimization, and has developed several proven metabolic pathways for chassis cells, providing ustomers in the fields of natural flavors, nutritional health, and biopharmaceuticals with products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2022
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.